Ionis Pharmaceuticals $575 Million Convertible Senior Notes Offering

San Diego – June 14, 2023 – Cooley advised Ionis Pharmaceuticals, a biotechnology company, in its $575 million aggregate principal amount of convertible senior notes. Partners Charlie Kim, Natalie Karam, Mischi a Marca and Jason Savich led the Cooley team.

Ionis will use proceeds from the notes to repurchase some of its 0.125% convertible senior notes due 2024, along with additional repurchases of the 2024 notes from time to time following the offering.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.